Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ruxolitinib

Known as: (3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile 
An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
A multitude of new agents for the treatment of hematologic malignancies has been introduced over the past decade. Hematologists… Expand
Is this relevant?
Review
2019
Review
2019
  • R. Roskoski
  • Pharmacological research
  • 2019
  • Corpus ID: 80625382
Because mutations, overexpression, and dysregulation of protein kinases play essential roles in the pathogenesis of many… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Review
2018
Review
2018
For patients with hematologic malignancies and disorders, allogeneic hematopoietic stem cell transplantation offers a potentially… Expand
Is this relevant?
Review
2018
Review
2018
BACKGROUND The present review is part of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study… Expand
  • table 1
  • table 2
Is this relevant?
Review
2017
Review
2017
Myeloproliferative neoplasms (MPN) include three main entities: Polycythemia Vera (PV), Essential Thrombocythemia (ET), and… Expand
  • figure 1
  • table 1
  • figure 2
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, was shown to have a clinical benefit in patients with… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is characterized by a gene-expression profile… Expand
  • figure 1
  • table 1
  • figure 3
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Ruxolitinib is a potent Janus kinase (JAK)1/JAK2 inhibitor that has demonstrated rapid reductions in splenomegaly and marked… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, has clinically significant activity in myelofibrosis… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Treatment options for myelofibrosis are limited. We evaluated the efficacy and safety of ruxolitinib, a potent and… Expand
  • table 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?